Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 May;18(5):572-585.
doi: 10.1016/j.jcmg.2024.11.005. Epub 2025 Feb 11.

Benchmarking Photon-Counting Computed Tomography Angiography Against Invasive Assessment of Coronary Stenosis: Implications for Severely Calcified Coronaries

Collaborators, Affiliations
Free article
Comparative Study

Benchmarking Photon-Counting Computed Tomography Angiography Against Invasive Assessment of Coronary Stenosis: Implications for Severely Calcified Coronaries

Rafail A Kotronias et al. JACC Cardiovasc Imaging. 2025 May.
Free article

Abstract

Background: Clinical guidelines do not recommend coronary computed tomographic angiography (CTA) in elderly patients or in the presence of heavy coronary calcification. Photon-counting coronary computed tomographic angiography (PCCTA) introduces ultrahigh in-plane resolution and multienergy imaging, but the ability of this technology to overcome these limitations is unclear.

Objectives: The authors evaluate the ability of PCCTA to quantitatively assess coronary luminal stenosis in the presence and absence of calcification, comparing both the ultrahigh-resolution (UHR)-PCCTA and the multienergy standard-resolution (SR)-PCCTA with the criterion-standard 3-dimensional invasive quantitative coronary angiography (3D QCA).

Methods: The authors included 100 patients who had both PCCTA and invasive coronary angiography (ICA). They comparatively evaluated luminal diameter stenosis with PCCTA and 3D QCA, anatomic disease severity (according to CAD-RADS [Coronary Artery Disease-Reporting and Data System]) and the diagnostic performance of PCCTA in identifying coronary arteries with ≥50% diameter stenosis on 3D QCA requiring invasive hemodynamic severity evaluation and/or revascularization.

Results: The authors analyzed 257 vessels and 343 plaques. UHR-PCCTA luminal evaluation relative to 3D QCA was more precise than SR-PCCTA (median difference: 3% [Q1-Q3: 1%-6%] vs 6% [Q1-Q3: 2%-11%]; P < 0.001), particularly in severely calcified arteries (median difference 3% [Q1-Q3: 1%-6%] vs 6% [Q1-Q3: 3%-13%]; P = 0.002). Per-vessel agreement for CAD-RADS between UHR-PCCTA and 3D QCA was near-perfect (κ = 0.90 [Q1-Q3: 0.84-0.95]; P < 0.001), and it was substantial for SR-PCCTA (κ = 0.63 [Q1-Q3: 0.54-0.71]; P < 0.001), especially in severely calcified arteries: κ = 0.90 (Q1-Q3: 0.83-0.97; P < 0.001) and κ = 0.67 (Q1-Q3: 0.56-0.77; P < 0.001), respectively. Per-vessel diagnostic performance of SR- and UHR-PCCTA was excellent: AUC: 0.94 (95% CI: 0.91-0.98; P < 0.001) and 0.99 (95% CI: 0.98-1.00; P < 0.001), respectively. UHR-PCCTA diagnostically outperformed SR-PCCTA: ΔAUC: 0.05 (95% CI: 0.01-0.08; P = 0.01).

Conclusions: PCCTA compares favorably with ICA for lumen assessment and anatomic disease severity classification in patients presenting with acute coronary syndrome or patients referred for ICA. UHR-PCCTA luminal evaluation is superior to SR-PCCTA, especially in patients with heavy coronary calcification. UHR-PCCTA has excellent diagnostic performance in identifying coronary arteries with ≥50% luminal stenosis on 3D QCA, outperforming standard-resolution imaging.

Keywords: 3D QCA; coronary CTA; diagnostic performance; photon-counting.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures This work was supported by British Heart Foundation grants FS/CRTF/23/24460, CH/F/21/90009, and RG/F/21/110040, the Onassis Foundation, the Oxford Biomedical Research Centre, and the NIHR Oxford Biomedical Research Centre Imaging and Cardiovascular Themes. The University of Oxford has a collaboration agreement with Siemens that allows access to advanced image analysis tools and prototype applications for research use. Dr Antoniades holds several patents (US10,695,023B2, PCT/GB2017/053262, GB2018/1818049.7, GR20180100490, GR20180100510) licensed to Caristo Diagnostics; was recent Chair of the British Atherosclerosis Society; and has received honoraria from Amarin, Silence Therapeutics, Abcentra, Amgen, Nodthera, and Caristo Diagnostic. Drs Antoniades, Channon, and Neubauer are founders, shareholders, directors, and consultants of Caristo Diagnostics, a University of Oxford Spinout company. Dr Kotronias has received honoraria from Abbott. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Publication types

MeSH terms